Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice - PubMed
- ️Sat Jan 01 2000
Comparative Study
Effects of repeated fluoxetine and citalopram administration on cytokine release in C57BL/6 mice
M Kubera et al. Psychiatry Res. 2000.
Abstract
This study examines the effects of repeated administration of the selective serotonin reuptake inhibitors (SSRIs), fluoxetine and citalopram (10 mg/kg, i.p.), on immunoreactivity in C57BL/6 mice. Immune functions were evaluated by the ability of splenocytes to reduce a tetrazolium salt to formazan (MTT test), to proliferate, and to produce cytokines, including interleukin (IL)-1, IL-2, IL-4, IL-6, IL-10 and interferon gamma (IFN gamma). Citalopram administered for 1, 2 and 4 weeks stimulates the proliferative activity of splenocytes and suppresses their ability to secrete the anti-inflammatory cytokine IL-4. Fluoxetine administration for 1 and 2 weeks, but not 4 weeks, stimulates the proliferative activity of splenocytes, whereas a 4-week administration of fluoxetine suppresses the secretion of IL-4. Four weeks of prolonged administration of citalopram and fluoxetine induces a significant increase in the production of IL-6 and IL-10, a cytokine with immunosuppressive and anti-inflammatory activities. The results show that, in C57BL/6 mice, the immunomodulatory effects of SSRIs depend on the SSRI used and the duration of administration.
Similar articles
-
Kubera M, Holan V, Mathison R, Maes M. Kubera M, et al. Psychoneuroendocrinology. 2000 Nov;25(8):785-97. doi: 10.1016/s0306-4530(00)00026-3. Psychoneuroendocrinology. 2000. PMID: 10996474
-
Sacre S, Medghalchi M, Gregory B, Brennan F, Williams R. Sacre S, et al. Arthritis Rheum. 2010 Mar;62(3):683-93. doi: 10.1002/art.27304. Arthritis Rheum. 2010. PMID: 20131240
-
Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Pacher P, et al. Curr Med Chem. 1999 Jun;6(6):469-80. Curr Med Chem. 1999. PMID: 10213794 Review.
-
The pharmacogenetics of the selective serotonin reuptake inhibitors.
Brøsen K. Brøsen K. Clin Investig. 1993 Dec;71(12):1002-9. doi: 10.1007/BF00180032. Clin Investig. 1993. PMID: 8124052 Review.
Cited by
-
Maes M, Fišar Z, Medina M, Scapagnini G, Nowak G, Berk M. Maes M, et al. Inflammopharmacology. 2012 Jun;20(3):127-50. doi: 10.1007/s10787-011-0111-7. Epub 2012 Jan 24. Inflammopharmacology. 2012. PMID: 22271002 Review.
-
Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing.
Burchett JR, Dailey JM, Kee SA, Pryor DT, Kotha A, Kankaria RA, Straus DB, Ryan JJ. Burchett JR, et al. Cells. 2022 Sep 27;11(19):3031. doi: 10.3390/cells11193031. Cells. 2022. PMID: 36230993 Free PMC article. Review.
-
K C, M M, M K. K C, et al. Neurotox Res. 2021 Aug;39(4):1211-1226. doi: 10.1007/s12640-021-00367-5. Epub 2021 May 4. Neurotox Res. 2021. PMID: 33945102 Free PMC article.
-
Yoon JP, Yoon JW, Kim HM, Oh JH. Yoon JP, et al. Tissue Eng Regen Med. 2022 Aug;19(4):853-860. doi: 10.1007/s13770-022-00444-6. Epub 2022 Apr 19. Tissue Eng Regen Med. 2022. PMID: 35438456 Free PMC article.
-
Inflammation in depression: is adiposity a cause?
Shelton RC, Miller AH. Shelton RC, et al. Dialogues Clin Neurosci. 2011;13(1):41-53. doi: 10.31887/DCNS.2011.13.1/rshelton. Dialogues Clin Neurosci. 2011. PMID: 21485745 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources